JP Morgan Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $181
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama maintains an Overweight rating on Neurocrine Biosciences (NASDAQ:NBIX) and raises the price target from $173 to $181.
August 07, 2024 | 5:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan analyst Anupam Rama maintains an Overweight rating on Neurocrine Biosciences (NASDAQ:NBIX) and raises the price target from $173 to $181.
The raised price target and maintained Overweight rating from a reputable analyst at JP Morgan is likely to positively influence investor sentiment and drive short-term price appreciation for NBIX.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100